Journal Article

Improvement in Highly Active Antiretroviral Therapy—Induced Metabolic Syndrome by Treatment with Pioglitazone but Not with Fenofibrate: A 2 × 2 Factorial, Randomized, Double-Blinded, Placebo-Controlled Trial

Alina Gavrila, William Hsu, Sotirios Tsiodras, John Doweiko, Shiva Gautam, Lizabeth Martin, Alan C. Moses, Adolf W. Karchmer and Christos S. Mantzoros

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 40, issue 5, pages 745-749
Published in print March 2005 | ISSN: 1058-4838
Published online March 2005 | e-ISSN: 1537-6591 | DOI: https://dx.doi.org/10.1086/427697
Improvement in Highly Active Antiretroviral Therapy—Induced Metabolic Syndrome by Treatment with Pioglitazone but Not with Fenofibrate: A 2 × 2 Factorial, Randomized, Double-Blinded, Placebo-Controlled Trial

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We designed a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients with highly active antiretroviral therapy (HAART)–induced metabolic syndrome. We found that the administration of pioglitazone, but not fenofibrate, improved insulin resistance, blood pressure, and lipid profile over a 12-month period.

Journal Article.  2462 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.